Accelerated versus standard epirubicin followed by cyclophosphamide, methotrexate, and fluorouracil or capecitabine as adjuvant therapy for breast cancer (UK TACT2; CRUK/05/19): quality of life results from a multicentre, phase 3, open-label, randomised, controlled trial

Autor:	Velikova, Galina1 (AUTHOR) g.velikova@leeds.ac.uk, Morden, James P1 (AUTHOR), Haviland, Joanne S2 (AUTHOR), Emery, Charlotte2 (AUTHOR), Barrett-Lee, Peter3 (AUTHOR), Earl, Helena4,5 (AUTHOR), Bloomfield, David6 (AUTHOR), Brunt, Adrian Murray7,8 (AUTHOR), Canney, Peter9 (AUTHOR), Coleman, Robert10 (AUTHOR), Verrill, Mark11 (AUTHOR), Wardley, Andrew12 (AUTHOR), Bertelli, Gianfilippo6 (AUTHOR), Ellis, Paul13 (AUTHOR), Stein, Rob14 (AUTHOR), Bliss, Judith M2 (AUTHOR), Cameron, David15 (AUTHOR)
Zdroj:	Lancet Oncology. Dec2023, Vol. 24 Issue 12, p1359-1374. 16p.
Databáze:	Academic Search Ultimate
Externí odkaz:	Zobrazit plný text záznamu